Cargando…
Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting
Background: Inhaled corticosteroid (ICS)-containing medications slow rate of decline of FEV(1). Blood eosinophil (EOS) levels are associated with the degree of exacerbation reduction with ICS. Purpose: We investigated whether FEV(1) decline differs between patients with and without ICS, stratified b...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536812/ https://www.ncbi.nlm.nih.gov/pubmed/31213788 http://dx.doi.org/10.2147/COPD.S200919 |
_version_ | 1783421852550430720 |
---|---|
author | Whittaker, Hannah R Müllerova, Hana Jarvis, Deborah Barnes, Neil C Jones, Paul W Compton, Chris H Kiddle, Steven J Quint, Jennifer K |
author_facet | Whittaker, Hannah R Müllerova, Hana Jarvis, Deborah Barnes, Neil C Jones, Paul W Compton, Chris H Kiddle, Steven J Quint, Jennifer K |
author_sort | Whittaker, Hannah R |
collection | PubMed |
description | Background: Inhaled corticosteroid (ICS)-containing medications slow rate of decline of FEV(1). Blood eosinophil (EOS) levels are associated with the degree of exacerbation reduction with ICS. Purpose: We investigated whether FEV(1) decline differs between patients with and without ICS, stratified by blood EOS level. Patients and methods: The UK Clinical Practice Research Datalink (primary care records) and Hospital Episode Statistics (hospital records) were used to identify COPD patients aged 35 years or older, who were current or ex-smokers with ≥2 FEV(1) measurements ≥6 months apart. Prevalent ICS use and the nearest EOS count to start of follow-up were identified. Patients were classified at baseline as higher stratum EOS (≥150 cell/µL) on ICS; higher stratum EOS not on ICS; lower stratum EOS (<150 cells/µL) on ICS; and lower stratum EOS not on ICS. In addition, an incident ICS cohort was used to investigate the rate of FEV(1) change by EOS and incident ICS use. Mixed-effects linear regression was used to compare rates of FEV(1) change in mL/year. Results: A total of 26,675 COPD patients met our inclusion criteria (median age 69, 46% female). The median duration of follow up was 4.2 years. The rate of FEV(1) change in prevalent ICS users was slower than non-ICS users (−12.6 mL/year vs −21.1 mL/year; P =0.001). The rate of FEV(1) change was not significantly different when stratified by EOS level. The rate of FEV(1) change in incident ICS users increased (+4.2 mL/year) vs −21.2 mL/year loss in non-ICS users; P<0.001. In patients with high EOS, incident ICS patients showed an increase in FEV(1) (+12 mL/year) compared to non-ICS users whose FEV(1) decreased (−20.8 mL/year); P<0.001. No statistical difference was seen in low EOS patients. Incident ICS use is associated with an improvement in FEV(1) change, however, over time this association is lost. Conclusion: Regardless of blood EOS level, prevalent ICS use is associated with slower rates of FEV(1) decline in COPD. |
format | Online Article Text |
id | pubmed-6536812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65368122019-06-18 Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting Whittaker, Hannah R Müllerova, Hana Jarvis, Deborah Barnes, Neil C Jones, Paul W Compton, Chris H Kiddle, Steven J Quint, Jennifer K Int J Chron Obstruct Pulmon Dis Original Research Background: Inhaled corticosteroid (ICS)-containing medications slow rate of decline of FEV(1). Blood eosinophil (EOS) levels are associated with the degree of exacerbation reduction with ICS. Purpose: We investigated whether FEV(1) decline differs between patients with and without ICS, stratified by blood EOS level. Patients and methods: The UK Clinical Practice Research Datalink (primary care records) and Hospital Episode Statistics (hospital records) were used to identify COPD patients aged 35 years or older, who were current or ex-smokers with ≥2 FEV(1) measurements ≥6 months apart. Prevalent ICS use and the nearest EOS count to start of follow-up were identified. Patients were classified at baseline as higher stratum EOS (≥150 cell/µL) on ICS; higher stratum EOS not on ICS; lower stratum EOS (<150 cells/µL) on ICS; and lower stratum EOS not on ICS. In addition, an incident ICS cohort was used to investigate the rate of FEV(1) change by EOS and incident ICS use. Mixed-effects linear regression was used to compare rates of FEV(1) change in mL/year. Results: A total of 26,675 COPD patients met our inclusion criteria (median age 69, 46% female). The median duration of follow up was 4.2 years. The rate of FEV(1) change in prevalent ICS users was slower than non-ICS users (−12.6 mL/year vs −21.1 mL/year; P =0.001). The rate of FEV(1) change was not significantly different when stratified by EOS level. The rate of FEV(1) change in incident ICS users increased (+4.2 mL/year) vs −21.2 mL/year loss in non-ICS users; P<0.001. In patients with high EOS, incident ICS patients showed an increase in FEV(1) (+12 mL/year) compared to non-ICS users whose FEV(1) decreased (−20.8 mL/year); P<0.001. No statistical difference was seen in low EOS patients. Incident ICS use is associated with an improvement in FEV(1) change, however, over time this association is lost. Conclusion: Regardless of blood EOS level, prevalent ICS use is associated with slower rates of FEV(1) decline in COPD. Dove 2019-05-23 /pmc/articles/PMC6536812/ /pubmed/31213788 http://dx.doi.org/10.2147/COPD.S200919 Text en © 2019 Whittaker et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Whittaker, Hannah R Müllerova, Hana Jarvis, Deborah Barnes, Neil C Jones, Paul W Compton, Chris H Kiddle, Steven J Quint, Jennifer K Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting |
title | Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting |
title_full | Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting |
title_fullStr | Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting |
title_full_unstemmed | Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting |
title_short | Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting |
title_sort | inhaled corticosteroids, blood eosinophils, and fev(1) decline in patients with copd in a large uk primary health care setting |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536812/ https://www.ncbi.nlm.nih.gov/pubmed/31213788 http://dx.doi.org/10.2147/COPD.S200919 |
work_keys_str_mv | AT whittakerhannahr inhaledcorticosteroidsbloodeosinophilsandfev1declineinpatientswithcopdinalargeukprimaryhealthcaresetting AT mullerovahana inhaledcorticosteroidsbloodeosinophilsandfev1declineinpatientswithcopdinalargeukprimaryhealthcaresetting AT jarvisdeborah inhaledcorticosteroidsbloodeosinophilsandfev1declineinpatientswithcopdinalargeukprimaryhealthcaresetting AT barnesneilc inhaledcorticosteroidsbloodeosinophilsandfev1declineinpatientswithcopdinalargeukprimaryhealthcaresetting AT jonespaulw inhaledcorticosteroidsbloodeosinophilsandfev1declineinpatientswithcopdinalargeukprimaryhealthcaresetting AT comptonchrish inhaledcorticosteroidsbloodeosinophilsandfev1declineinpatientswithcopdinalargeukprimaryhealthcaresetting AT kiddlestevenj inhaledcorticosteroidsbloodeosinophilsandfev1declineinpatientswithcopdinalargeukprimaryhealthcaresetting AT quintjenniferk inhaledcorticosteroidsbloodeosinophilsandfev1declineinpatientswithcopdinalargeukprimaryhealthcaresetting |